| Application no. and date | 17156985.8 (espacenet) (Federated) (European Patent Register), 20111202 | | Patent/reg. no. and date | DK/EP 3222280, 20210120 | | Publication date | 20170927 | | Priority no. and date | US 419395 P, 20101203 | | EP pub. no. and date |
EP 3222280 20170927 | | Effective date | | | Applicant/owner | Nalpropion Pharmaceuticals LLC, 10 North Park Place, Suite 201
Morristown, NJ 07960, US | | Applicant ref. no. | P76363DK01 | | Inventor | DUNAYEVICH, Eduardo, 1030 Deep Wood Drive
Westlake Village, CA 91362, US,
FLANAGAN, Shawn, 14083 Via Corsini
San Diego, CA 92128, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 31/137 (2006.01) , A61K 31/485 (2006.01) , A61P 3/04 (2006.01) | | Title | FORØGELSE AF LÆGEMIDDELBIOTILGÆNGELIGHED I NALTREXONBEHANDLING | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
